Gradalis is dedicated to developing and commercializing “molecular” based personalized therapeutics that are tumor specific, more effective and less toxic than current treatment modalities.

Press Release Gradalis, Inc. Appoints Sunil Joshi Chief Executive Officer
Press Release Phase 2 of Vigil® and anti-PD-1 in NSCLC
Press Release Phase 2b of Vigil® in Ewing's Sarcoma
Press Release Presentation at ASCO 2015
Vigil®
Immunotherapies
Goal